Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A random...

by Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka‐Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Osamu Sekine, Masahiro Yoshimura, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Hiroshi Maegawa, the SUMS‐ADDIT‐1 Research group
Published 2019-07-01